ofloxacin has been researched along with Acute Bacterial Prostatitis in 62 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 9.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "To compare the safety and efficacy of levofloxacin 750 mg QD for 2 weeks or levofloxacin 750 mg QD for 3 weeks to levofloxacin 500 mg QD for 4 weeks in treating chronic bacterial prostatitis (CBP)." | 9.14 | Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. ( Fisher, AC; Kahn, JB; Nicholson, SC; Paglia, M; Peterson, J; Qin, Z, 2010) |
| "The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe." | 9.13 | Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008) |
| "For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome." | 9.13 | Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. ( Jeong, CW; Jeong, H; Lee, SE; Lim, DJ; Son, H, 2008) |
| "To evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis." | 9.13 | [Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. ( Guo, DF; Wang, HP; Zhang, HZ, 2008) |
| "Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily." | 9.12 | Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. ( Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F, 2007) |
| "Longqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients." | 9.12 | [Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. ( Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007) |
| "Subset analysis was done using a randomized, multicenter, double-blind, active control trial of 500 mg levofloxacin daily for 28 days vs 500 mg ciprofloxacin twice daily in 28 days in men with chronic bacterial prostatitis." | 9.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 9.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "To perform a Canadian multicenter randomized placebo-controlled trial to evaluate the safety and efficacy of 6 weeks of levofloxacin therapy compared with placebo in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 9.10 | Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. ( Barkin, J; Brock, G; Casey, RW; Clark, J; Downey, J; Flax, S; Goldfarb, B; Nickel, JC; Palmer, BW; Patrick, AB; Pommerville, PJ; Steinhoff, G; Zadra, J, 2003) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 9.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "The combination of levofloxacin and α1 adrenergic antagonist treatment is the current preferred choice for both bacterial and non-bacterial prostatitis." | 7.79 | Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. ( He, HX; He, Y; Qin, GD; Xiao, MZ; Yang, J; Zeng, Y; Zhou, YD, 2013) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 7.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "To evaluate the effect of levofloxacin (LVX) oral therapy on total serum prostate specific antigen (PSA) values in patients with histological prostatitis." | 7.72 | PSA decrease after levofloxacin therapy in patients with histological prostatitis. ( Bollito, E; Cracco, C; Guercio, S; Poggio, M; Scarpa, RM; Tarabuzzi, R; Terrone, C, 2004) |
| "Ofloxacin (OFLX), a new pyridonecarboxylic acid derivative for oral use, was administered in the treatment of 22 cases of bacterial prostatitis (acute 4, chronic 18)." | 7.67 | [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. ( Ando, K; Moriguchi, R; Naide, Y; Suzuki, K; Tamai, H, 1984) |
| "Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12." | 5.28 | [Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992) |
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 5.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0." | 5.16 | [Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction]. ( Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P, 2012) |
| "To compare the safety and efficacy of levofloxacin 750 mg QD for 2 weeks or levofloxacin 750 mg QD for 3 weeks to levofloxacin 500 mg QD for 4 weeks in treating chronic bacterial prostatitis (CBP)." | 5.14 | Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. ( Fisher, AC; Kahn, JB; Nicholson, SC; Paglia, M; Peterson, J; Qin, Z, 2010) |
| "For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome." | 5.13 | Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. ( Jeong, CW; Jeong, H; Lee, SE; Lim, DJ; Son, H, 2008) |
| "The aim of this study was to confirm further the efficacy and safety of levofloxacin in patients with chronic bacterial prostatitis (CBP) in Europe." | 5.13 | Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. ( Botto, H; Naber, KG; Roscher, K; Schaefer, V, 2008) |
| "To evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis." | 5.13 | [Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. ( Guo, DF; Wang, HP; Zhang, HZ, 2008) |
| "Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily." | 5.12 | Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. ( Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F, 2007) |
| "Longqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients." | 5.12 | [Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. ( Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007) |
| "Subset analysis was done using a randomized, multicenter, double-blind, active control trial of 500 mg levofloxacin daily for 28 days vs 500 mg ciprofloxacin twice daily in 28 days in men with chronic bacterial prostatitis." | 5.11 | Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. ( Kahn, JB; Schaeffer, AJ; Tennenberg, AM; Wu, SC, 2005) |
| "To perform a Canadian multicenter randomized placebo-controlled trial to evaluate the safety and efficacy of 6 weeks of levofloxacin therapy compared with placebo in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 5.10 | Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. ( Barkin, J; Brock, G; Casey, RW; Clark, J; Downey, J; Flax, S; Goldfarb, B; Nickel, JC; Palmer, BW; Patrick, AB; Pommerville, PJ; Steinhoff, G; Zadra, J, 2003) |
| "To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis." | 5.10 | Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. ( Bundrick, W; Heron, SP; Kahn, JB; Ray, P; Schiff, WM; Tennenberg, AM; Wiesinger, BA; Wright, PA; Wu, SC; Zadeikis, N, 2003) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 5.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "The combination of levofloxacin and α1 adrenergic antagonist treatment is the current preferred choice for both bacterial and non-bacterial prostatitis." | 3.79 | Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. ( He, HX; He, Y; Qin, GD; Xiao, MZ; Yang, J; Zeng, Y; Zhou, YD, 2013) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 3.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "Men with prostatitis-like symptoms and any bacteria localized to prostate specific specimens were treated with levofloxacin or ciprofloxacin for 4 weeks with 6 months of followup." | 3.74 | Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. ( Nickel, JC; Xiang, J, 2008) |
| "To evaluate the effect of levofloxacin (LVX) oral therapy on total serum prostate specific antigen (PSA) values in patients with histological prostatitis." | 3.72 | PSA decrease after levofloxacin therapy in patients with histological prostatitis. ( Bollito, E; Cracco, C; Guercio, S; Poggio, M; Scarpa, RM; Tarabuzzi, R; Terrone, C, 2004) |
| "Ofloxacin (OFLX), a new pyridonecarboxylic acid derivative for oral use, was administered in the treatment of 22 cases of bacterial prostatitis (acute 4, chronic 18)." | 3.67 | [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. ( Ando, K; Moriguchi, R; Naide, Y; Suzuki, K; Tamai, H, 1984) |
| "Ofloxacin, a new fluoroquinolone, was given to fifty patients (29 females and 21 males) aged 25 to 86 years with urinary tract infection or prostatitis." | 3.67 | [Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections]. ( Acar, JF; Guibert, J, 1986) |
| "In this study, 20 men suffering from acute nongonococcal epididymitis were treated with ofloxacin 200mg bid given orally for 2 weeks." | 3.67 | Acute nongonococcal epididymitis. Aetiological and therapeutic aspects. ( Garbe, C; Schiefer, HG; Weidner, W, 1987) |
| "Prednisone in combination with an antibiotic can effectively relieve pain and voiding symptoms, improve QOL and reduce WBC in the EPS of CNP patients, and therefore well deserves to be recommended in clinical application." | 2.74 | [Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]. ( Hou, Y; Lü, C; Wu, ZP; Xiao, N; Yang, MG; Zhao, XK, 2009) |
| "Tosufloxacin was as effective as levofloxacin when administered twice daily for 2 days as prophylaxis for TBP, which suggests that this regimen is useful for reducing the clinical and febrile infection rate following TBP." | 2.73 | Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. ( Ishitoya, S; Kamoto, T; Ogawa, O; Okumura, K; Segawa, T; Yamamoto, S, 2008) |
| "Levofloxacin has such an activity profile." | 2.69 | A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. ( Boccumini, L; Corrado, M; Drusano, GL; Gombert, M; Kahn, J; North, D; Oefelein, M; Preston, SL; Van Guilder, M; Weisinger, B, 2000) |
| " In practice, adverse events (AEs) of BCG therapy could restrict its prescription by urologists." | 2.48 | [Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology]. ( Davin, JL; Irani, J; Larré, S; Moreau, JL; Neuzillet, Y; Pfister, C; Pignot, G; Rouprêt, M; Soulié, M; Wallerand, H, 2012) |
| "Prostate cancer was detected in 20% of patients with a clinically relevant PSA decline." | 1.37 | Antimicrobial therapy for asymptomatic patients with elevated prostate-specific antigen: can the change in prostate-specific antigen reliably guide prostate biopsy decisions? ( Abdelhamid, M; Emran, A; Kamal, A; Mosharafa, A; Torky, M, 2011) |
| "coli." | 1.37 | Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. ( Baba, S; Fujita, T; Iwamura, M; Kimura, M; Kurosaka, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| "Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms." | 1.35 | [Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009) |
| "Prostate cancer was found in 10." | 1.33 | Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml. ( Cetinkaya, M; Inal, G; Kaygisiz, O; Koşan, M; Oztürk, B; Uğurlu, O, 2006) |
| "Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12." | 1.28 | [Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (11.29) | 18.7374 |
| 1990's | 8 (12.90) | 18.2507 |
| 2000's | 32 (51.61) | 29.6817 |
| 2010's | 15 (24.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naber, KG | 3 |
| Roscher, K | 2 |
| Botto, H | 1 |
| Schaefer, V | 1 |
| Yang, MG | 1 |
| Zhao, XK | 1 |
| Wu, ZP | 1 |
| Xiao, N | 1 |
| Lü, C | 1 |
| Hou, Y | 1 |
| Shigemura, K | 1 |
| Yasufuku, T | 1 |
| Yamashita, M | 1 |
| Arakawa, S | 1 |
| Fujisawa, M | 1 |
| Bartoletti, R | 2 |
| Cai, T | 2 |
| Paglia, M | 1 |
| Peterson, J | 1 |
| Fisher, AC | 1 |
| Qin, Z | 1 |
| Nicholson, SC | 1 |
| Kahn, JB | 3 |
| Mirone, V | 1 |
| Magri, V | 1 |
| Marras, E | 1 |
| Skerk, V | 1 |
| Markotić, A | 1 |
| Restelli, A | 1 |
| Garlaschi, MC | 1 |
| Perletti, G | 1 |
| Wagenlehner, F | 1 |
| Mazzoli, S | 1 |
| Meacci, F | 1 |
| Boddi, V | 1 |
| Mondaini, N | 1 |
| Malossini, G | 1 |
| Panas, M | 1 |
| Karadima, G | 1 |
| Kalfakis, N | 1 |
| Vassilopoulos, D | 1 |
| Minamida, S | 1 |
| Satoh, T | 1 |
| Tabata, K | 1 |
| Kimura, M | 1 |
| Tsumura, H | 1 |
| Kurosaka, S | 1 |
| Matsumoto, K | 1 |
| Fujita, T | 1 |
| Iwamura, M | 1 |
| Baba, S | 1 |
| Torky, M | 1 |
| Mosharafa, A | 1 |
| Emran, A | 1 |
| Kamal, A | 1 |
| Abdelhamid, M | 1 |
| Faydaci, G | 1 |
| Eryildirim, B | 1 |
| Tarhan, F | 1 |
| Goktas, C | 1 |
| Tosun, C | 1 |
| Kuyumcuoglu, U | 1 |
| Oliveira-Reis, L | 1 |
| Zhang, ZC | 1 |
| Jin, FS | 1 |
| Liu, DM | 1 |
| Shen, ZJ | 1 |
| Sun, YH | 1 |
| Guo, YL | 1 |
| La Vignera, S | 1 |
| Condorelli, RA | 1 |
| Calogero, AE | 1 |
| Bellanca, S | 1 |
| Salmeri, M | 1 |
| Vicari, E | 2 |
| Neuzillet, Y | 1 |
| Rouprêt, M | 1 |
| Wallerand, H | 1 |
| Pignot, G | 1 |
| Larré, S | 1 |
| Irani, J | 1 |
| Davin, JL | 1 |
| Moreau, JL | 1 |
| Soulié, M | 1 |
| Pfister, C | 1 |
| Kuz'menko, VV | 1 |
| Kuz'menko, AV | 1 |
| Kurnosova, NV | 1 |
| Wang, L | 1 |
| Liang, P | 1 |
| Yang, W | 1 |
| Zhou, P | 1 |
| Huang, XK | 1 |
| Liu, JW | 1 |
| Chao, WF | 1 |
| Yang, H | 1 |
| Wang, QT | 1 |
| Qin, GD | 1 |
| Xiao, MZ | 1 |
| Zhou, YD | 1 |
| Yang, J | 1 |
| He, HX | 1 |
| He, Y | 1 |
| Zeng, Y | 1 |
| Sachs, HP | 1 |
| Zhou, LQ | 1 |
| Shen, M | 1 |
| Zhao, Y | 1 |
| Seo, SI | 1 |
| Lee, SJ | 1 |
| Kim, JC | 1 |
| Choi, YJ | 1 |
| SW, SW | 1 |
| Hwang, TK | 1 |
| Cho, YH | 1 |
| Jeon, SS | 1 |
| Woo, SH | 1 |
| Hyun, JH | 1 |
| Choi, HY | 1 |
| Chai, SE | 1 |
| Bundrick, W | 1 |
| Heron, SP | 1 |
| Ray, P | 1 |
| Schiff, WM | 1 |
| Tennenberg, AM | 2 |
| Wiesinger, BA | 1 |
| Wright, PA | 1 |
| Wu, SC | 2 |
| Zadeikis, N | 1 |
| Nickel, JC | 3 |
| Downey, J | 2 |
| Clark, J | 2 |
| Casey, RW | 1 |
| Pommerville, PJ | 1 |
| Barkin, J | 1 |
| Steinhoff, G | 1 |
| Brock, G | 1 |
| Patrick, AB | 1 |
| Flax, S | 1 |
| Goldfarb, B | 1 |
| Palmer, BW | 1 |
| Zadra, J | 1 |
| Ginsburg, AS | 1 |
| Woolwine, SC | 1 |
| Hooper, N | 1 |
| Benjamin, WH | 1 |
| Bishai, WR | 1 |
| Dorman, SE | 1 |
| Sterling, TR | 1 |
| Guercio, S | 1 |
| Terrone, C | 1 |
| Tarabuzzi, R | 1 |
| Poggio, M | 1 |
| Cracco, C | 1 |
| Bollito, E | 1 |
| Scarpa, RM | 1 |
| Schaeffer, AJ | 1 |
| Smelov, V | 1 |
| Perekalina, T | 1 |
| Artemenko, N | 1 |
| Smelova, N | 1 |
| Ukleeva, G | 1 |
| Gorelov, A | 1 |
| Pust, RA | 1 |
| Ackenheil-Koppe, HR | 1 |
| Gilbert, P | 1 |
| Weidner, W | 2 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Olapade-Olaopa, EO | 1 |
| Adebayo, SA | 1 |
| Kaygisiz, O | 1 |
| Uğurlu, O | 1 |
| Koşan, M | 1 |
| Inal, G | 1 |
| Oztürk, B | 1 |
| Cetinkaya, M | 1 |
| Xu, H | 1 |
| Shang, XJ | 1 |
| Cai, X | 1 |
| Teng, WH | 1 |
| Huang, YF | 1 |
| Giannarini, G | 1 |
| Mogorovich, A | 1 |
| Valent, F | 1 |
| Morelli, G | 1 |
| De Maria, M | 1 |
| Manassero, F | 1 |
| Barbone, F | 1 |
| Selli, C | 1 |
| Xiang, J | 1 |
| Shigehara, K | 1 |
| Miyagi, T | 1 |
| Nakashima, T | 2 |
| Shimamura, M | 1 |
| Guo, DF | 1 |
| Zhang, HZ | 1 |
| Wang, HP | 1 |
| Jeong, CW | 1 |
| Lim, DJ | 1 |
| Son, H | 1 |
| Lee, SE | 1 |
| Jeong, H | 1 |
| Kobayashi, M | 1 |
| Nukui, A | 1 |
| Morita, T | 1 |
| Yamamoto, S | 1 |
| Ishitoya, S | 1 |
| Segawa, T | 1 |
| Kamoto, T | 1 |
| Okumura, K | 1 |
| Ogawa, O | 1 |
| Hara, S | 1 |
| Nakasu, H | 1 |
| Suzuki, K | 2 |
| Tamai, H | 1 |
| Naide, Y | 1 |
| Ando, K | 1 |
| Moriguchi, R | 1 |
| Espiritu, J | 1 |
| Walton, T | 1 |
| Ohkawa, M | 1 |
| Yamaguchi, K | 1 |
| Tokunaga, S | 1 |
| Shoda, R | 1 |
| Pfau, A | 1 |
| Hennenfent, BR | 1 |
| Feliciano, AE | 1 |
| Nishimura, T | 1 |
| Abe, H | 1 |
| Ito, H | 1 |
| Ikeda, K | 1 |
| Oka, F | 1 |
| Yamamoto, M | 1 |
| Drusano, GL | 1 |
| Preston, SL | 1 |
| Van Guilder, M | 1 |
| North, D | 1 |
| Gombert, M | 1 |
| Oefelein, M | 1 |
| Boccumini, L | 1 |
| Weisinger, B | 1 |
| Corrado, M | 1 |
| Kahn, J | 1 |
| Johnston, B | 1 |
| Karazanashvili, G | 1 |
| Managadze, L | 1 |
| Trinchiere, A | 1 |
| Bravo, JL | 1 |
| Horiba, M | 1 |
| Asakawa, M | 1 |
| Yasumoto, R | 1 |
| Cox, CE | 1 |
| Schiefer, HG | 1 |
| Garbe, C | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis[NCT00402688] | Phase 3 | 242 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486] | 1,257 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis[NCT00236808] | Phase 3 | 383 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Study to Understand the Treatment Patterns in Patients With Chronic Bacterial Prostatitis (Category II), Chronic Pelvic Pain (Category IIIA, IIIB)Treataprost Added to Standard Antibiotic Treatment in Real-life Clinical Practice[NCT05306314] | 140 participants (Anticipated) | Observational | 2022-04-15 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy. (NCT00402688)
Timeframe: Posttherapy Visit (Study Day 33-36)
| Intervention | Participants (Number) |
|---|---|
| Levofloxacin 750mg for 2 Weeks | 46 |
| Levofloxacin 750mg for 3 Weeks | 48 |
| Levofloxacin 500mg for 4 Weeks | 52 |
Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit (NCT00402688)
Timeframe: Poststudy Telephone contact at 3 Months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Clinical Success | Failure | Unable to Evaluate | Missing | |
| Levofloxacin 500mg for 4 Weeks | 38 | 4 | 1 | 9 |
| Levofloxacin 750mg for 2 Weeks | 30 | 8 | 0 | 8 |
| Levofloxacin 750mg for 3 Weeks | 24 | 6 | 1 | 17 |
Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit (NCT00402688)
Timeframe: Poststudy Telephone Contact at 6 Months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Clinical Success | Failure | Unable to Evaluate | Missing | |
| Levofloxacin 500mg for 4 Weeks | 31 | 6 | 1 | 14 |
| Levofloxacin 750mg for 2 Weeks | 19 | 10 | 1 | 16 |
| Levofloxacin 750mg for 3 Weeks | 19 | 4 | 1 | 24 |
Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit (NCT00402688)
Timeframe: Poststudy Telephone contact at 6 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Clinical Success | Failure | Unable to Evaluate | Missing | |
| Levofloxacin 500mg for 4 Weeks | 44 | 5 | 1 | 2 |
| Levofloxacin 750mg for 2 Weeks | 38 | 3 | 0 | 5 |
| Levofloxacin 750mg for 3 Weeks | 32 | 12 | 1 | 3 |
Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation. (NCT00402688)
Timeframe: Posttherapy Visit (Study Day 33-36)
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dysuria (n=35, 43, 42) | Suprapubic discomfort (n=41, 36, 45) | Painful ejaculation (n=32, 39, 34) | Low back pain (n=43, 44, 44) | Perineal discomfort (n=40, 42, 50) | Frequency (n=58, 63, 62) | Urgency (n=48, 52, 58) | Hesitancy (n=37, 39, 54) | Decreased urinary stream (n=50, 47, 52) | Urinary retention (n=24, 26, 27) | Pain on digital rectal examination (n=60, 59, 61) | Perineal tenderness or pain (n=44, 38, 43) | Chills (n=4, 5, 7) | Other (n=5, 8, 8) | Fever (n=3, 2, 1) | |
| Levofloxacin 500mg for 4 Weeks | 27 | 30 | 20 | 26 | 29 | 30 | 35 | 38 | 30 | 17 | 42 | 28 | 7 | 5 | 1 |
| Levofloxacin 750mg for 2 Weeks | 23 | 24 | 17 | 20 | 20 | 29 | 20 | 19 | 24 | 13 | 30 | 28 | 3 | 1 | 2 |
| Levofloxacin 750mg for 3 Weeks | 29 | 19 | 23 | 22 | 19 | 24 | 28 | 16 | 21 | 13 | 30 | 24 | 3 | 5 | 2 |
National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life). (NCT00402688)
Timeframe: Screening/Admission, On-Therapy, Week 3, Week 4, Posttherapy (Study Day 33-36)
| Intervention | Score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Screening/Admission (n=73, 74, 75) | On-Therapy (n=70, 70, 73) | Week 3 (Visit 2) (n=62, 65, 68) | Week 4 (Visit 3) (n=53, 57, 61) | Posttherapy (Visit 4) (n=70, 71, 71) | |
| Levofloxacin 500mg for 4 Weeks | 12.9 | 6.9 | 5.6 | 4.5 | 4.6 |
| Levofloxacin 750mg for 2 Weeks | 11.8 | 7.2 | 6.5 | 5.1 | 5.4 |
| Levofloxacin 750mg for 3 Weeks | 12.0 | 6.6 | 6.5 | 4.9 | 5.0 |
4 reviews available for ofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
[From cystitis to bacterial prostatitis: experience with levofloxacin].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cystitis; Double-Blind Method; Drug Therapy, Combinatio | 2009 |
[Diagnosis and management of adverse events occuring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Anti-Infective Agents, Urinary; Arthralgia; BC | 2012 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
[Role of levofloxacin in the treatment of urinary tract infections].
Topics: Anti-Infective Agents, Urinary; Female; Humans; Levofloxacin; Male; Ofloxacin; Prostatitis; Urinary | 2001 |
19 trials available for ofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Chronic Disease; Gram-Negative Bacteria; Gram-Po | 2008 |
[Corticoid combined with an antibiotic for chronic nonbacterial prostatitis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy | 2009 |
Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; L | 2010 |
[Does antibiotherapy prevent unnecessary prostate biopsies in patients with high PSA values?].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 2012 |
Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.
Topics: Adult; Anti-Bacterial Agents; Asian People; Ciprofloxacin; Escherichia coli Infections; Humans; Levo | 2012 |
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin; | 2012 |
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Double-Blind Met | 2003 |
Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial.
Topics: Adult; Aged; Anti-Infective Agents; Chronic Disease; Double-Blind Method; Humans; Levofloxacin; Male | 2003 |
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; | 2005 |
[Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis].
Topics: Adult; Chronic Disease; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Phytotherapy; Prostatiti | 2007 |
Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dioxolanes; Double-Blind Method; Fluoroquinolones; Hu | 2007 |
[Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis].
Topics: Adult; Anti-Infective Agents, Urinary; Capsules; Chronic Disease; Drug Therapy, Combination; Drugs, | 2008 |
Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Doxazosin; Drug Therapy, Combination; Hu | 2008 |
Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy; Cystitis; Fluoroq | 2008 |
Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum.
Topics: Adult; Aged; Chronic Disease; Humans; Leukocyte Count; Male; Middle Aged; Minocycline; Ofloxacin; Pr | 1993 |
A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Demography; Humans; Levofloxacin; Male; Middle Aged; | 2000 |
Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Doxycycline; Epididymitis; Femal | 2000 |
Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibodies, Bacterial; Bacteria; Bacterial In | 2001 |
Ofloxacin in the management of complicated urinary tract infections, including prostatitis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Carbenicillin; Drug Resistance, Microbial; | 1989 |
39 other studies available for ofloxacin and Acute Bacterial Prostatitis
| Article | Year |
|---|---|
Prophylactic use of isepamicin and levofloxacin for transrectal prostate biopsy: a retrospective single center study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy | 2009 |
[Chronic prostatitis and biofilm].
Topics: Adult; Biofilms; Chronic Disease; Ciprofloxacin; Contraception Behavior; Diet; Disease Susceptibilit | 2009 |
Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Drug Therap | 2010 |
[Practice management of chronic bacterial prostatitis with levofloxacin].
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Chronic Disease; Escherichia coli | 2011 |
Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus fa | 2011 |
Hereditary neuropathy unmasked by levofloxacin.
Topics: Anti-Bacterial Agents; Charcot-Marie-Tooth Disease; Diagnosis, Differential; Family Health; Humans; | 2011 |
Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Carba | 2011 |
Antimicrobial therapy for asymptomatic patients with elevated prostate-specific antigen: can the change in prostate-specific antigen reliably guide prostate biopsy decisions?
Topics: Aged; Anti-Bacterial Agents; Asymptomatic Diseases; Biopsy; Diagnostic Errors; Drug Administration S | 2011 |
[Prostate specific antigen decrease and prostate cancer diagnosis: recognizing the fundamental previous progresses and moving forward].
Topics: Anti-Bacterial Agents; Biopsy, Needle; Humans; Male; Ofloxacin; Prostate; Prostate-Specific Antigen; | 2012 |
Persistence of ultrasound alterations after antibiotic treatment with levofloxacin in patients with male accessory gland infection.
Topics: Adult; Anti-Bacterial Agents; Epididymis; Epididymitis; Genital Diseases, Male; Humans; Levofloxacin | 2012 |
[Correction of psychoemotional status in patients with chronic bacterial prostatitis].
Topics: Adult; Anti-Anxiety Agents; Anti-Infective Agents, Urinary; Biureas; Drug Therapy, Combination; Huma | 2012 |
Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Bacterial Agents; Drug Interactions; Escheric | 2013 |
Consider the cost when prescribing antibiotics.
Topics: Anti-Infective Agents, Urinary; Cost-Benefit Analysis; Doxycycline; Humans; Male; Ofloxacin; Prostat | 2002 |
[Detection of bacterial 16S rRAN gene in EPS of men with chronic pelvic pain syndrome and its clinical significance].
Topics: Anti-Bacterial Agents; Azithromycin; Chronic Disease; Humans; Levofloxacin; Male; Ofloxacin; Pelvic | 2003 |
Effects of androgen deprivation on chronic bacterial prostatitis in a rat model.
Topics: Androgen Antagonists; Animals; Anti-Infective Agents, Urinary; Castration; Chronic Disease; Enzyme I | 2003 |
Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy.
Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Aged, 80 and over; Antibi | 2003 |
The rapid development of fluoroquinolone resistance in M. tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, | 2003 |
PSA decrease after levofloxacin therapy in patients with histological prostatitis.
Topics: Aged; Anti-Bacterial Agents; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostate-Specific A | 2004 |
Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome.
Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Chronic Disease; Fluoroquinolones; Humans; Levofloxaci | 2005 |
Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Escherichia coli Infec | 1989 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; | 2006 |
Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Carcinoma; Diagnosis, Differential; Humans; Male; Middle Aged; | 2006 |
Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Escherichia coli; Gram-Positive Bacteria; Humans; Levofloxacin | 2008 |
Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.
Topics: Aged; Anti-Bacterial Agents; Biopsy, Needle; Blood; Carbapenems; Cephalosporins; Drug Resistance, Ba | 2008 |
Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis.
Topics: Aged; Anti-Bacterial Agents; Humans; Male; Ofloxacin; Prostate-Specific Antigen; Prostatic Neoplasms | 2008 |
[The investigation of prostatic fluid and tissue levels of DL-8280 and clinical study of DL-8280 in acute prostatitis].
Topics: Acute Disease; Adult; Anti-Infective Agents; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Prostat | 1984 |
[Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Evalu | 1984 |
Acute renal failure due to ofloxacin.
Topics: Acute Kidney Injury; Aged; Fatal Outcome; Humans; Male; Ofloxacin; Prostatitis | 1995 |
Oral ofloxacin: a critical review of the new drug application.
Topics: Administration, Oral; Escherichia coli Infections; Humans; Investigational New Drug Application; Mal | 1993 |
Changes in white blood cell counts in men undergoing thrice-weekly prostatic massage, microbial diagnosis and antimicrobial therapy for genitourinary complaints.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antibiotics, Antineoplastic; Bacterial Infections; Drug | 1998 |
IL-1ra versus IL-1 levels in prostatic fluid from prostatitis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Body Fluids; C | 1998 |
National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, U | 1999 |
Prostate-specific antigen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and nonsuspicious results of digital rectal examination.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Humans; Male; Mass Screening; Middle Aged; Ofloxacin | 2001 |
[Ofloxacin: a new ally in the treatment of urinary infections and bacterial prostatitis].
Topics: Bacterial Infections; Humans; Male; Ofloxacin; Prostatitis; Urinary Tract Infections | 1992 |
[Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis].
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Epididymitis; Escherichia coli; Humans; | 1992 |
Ofloxacin concentration in human benign prostatic tissue after oral administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Humans; Male; Ofloxacin; Prostate; Prostatic Hyperpla | 1988 |
Acute nongonococcal epididymitis. Aetiological and therapeutic aspects.
Topics: Acute Disease; Adolescent; Adult; Aging; Anti-Infective Agents; Epididymitis; Humans; Male; Middle A | 1987 |
[Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cystitis; Female; Humans; Male; Middle Age | 1986 |